| Income Statement | 2026-03-31 | 2025-03-31 | ||
|---|---|---|---|---|
| Total revenues | 1,269 | 486 | ||
| Research and development | 54,974 | 39,375 | ||
| General and administrative | 18,421 | 17,084 | ||
| Total operating expenses | 73,395 | 56,459 | ||
| Loss from operations | -72,126 | -55,973 | ||
| Interest income, net | 2,441 | 4,557 | ||
| Other income, net | 7 | 5 | ||
| Loss before income taxes | -69,678 | -51,411 | ||
| Income taxes | 7 | 7 | ||
| Net loss | -69,685 | -51,418 | ||
| Unrealized gain (loss) on marketable securities | -7 | 5 | ||
| Comprehensive loss | -69,692 | -51,413 | ||
| Basic EPS | -1.83 | -1.67 | ||
| Diluted EPS | -1.83 | -1.67 | ||
| Basic Average Shares | 38,073,926 | 30,877,029 | ||
| Diluted Average Shares | 38,073,926 | 30,877,029 | ||
Vistagen Therapeutics, Inc. (VTGN)
Vistagen Therapeutics, Inc. (VTGN)